J&J Medical Connect
RYBREVANT®

(amivantamab-vmjw)

J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

RYBREVANT® (amivantamab-vmjw)

Medical Information

Use of RYBREVANT in Pediatric Patients

Last Updated: 02/13/2026

SUMMARY

  • RYBREVANT (amivantamab-vmjw) is a low fucose, fully human immunoglobulin G1 (IgG1)-based bispecific antibody with immune cell-directing activity that targets epidermal growth factor receptor (EGFR) mutations and mesenchymal-epithelial transition (MET) mutations and amplifications in non-small cell lung cancer (NSCLC).1
  • The safety and efficacy of RYBREVANT have not been established in pediatric patients.2
  • Please refer to RYBREVANT product labeling for additional information.2

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and DERWENT Drug File (and/or other resources, including internal/external databases) conducted on 11 February 2026 did not identify any relevant citations pertaining to this topic.

References

Show
1 Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942-3953.  
2 RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi